Cardioprotection thread, page-599

Blimey, Rhino. You really want to see my mug again? Hah.

If this post gets a substantial number of likes, I'll create a video addressing the following topics

- rediscovered drugs
-- the value of clinical history
-- drive first-in-class products

- bisantrene mechanisms of action
-- the birth of two new drug classes
-- the death of the anthracene model

- FTO-inhibitor vs CPACS drugs
-- what they do and why they are important
-- how they are different
-- clinical and commercial competition
-- market size

- literature supporting success and mitigating risk in proving CPACS in the clinic
-- preclinical data
-- clinical data
(think of this like a systematic dot-connection to explain the clinical data for bisantrene with current understanding)

- conceptualizing CPACS value on a global scale
-- drivers of commercial success (boston research group)
-- amalgamation of everything to synthesize the reality of a commercially viable, clinically proven first-in-class FTO-inhibitor and first-in-class CPACS drug

I will ensure the quality and rigor is extensive. Done correctly, this will take a significant amount of my time. Please, only like this if you think it will provided substantial value to you and investors.